Overview of Inhalerx's Q4 2023 cash flow report

Inhalerx Limited (ASX: $IRX) has released its quarterly cash flow report for the quarter ended 31 December 2023. The report includes details of payments to related parties, such as $56K paid as salary and fees to key management personnel, and $21K paid in directors fees. The compliance statement confirms that the report has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

Executive commentary on the cash flow report

The entity expects to continue its operations and meet its business objectives. The report provides a true and fair view of the matters disclosed and has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A. The board has authorized the release of the report, ensuring compliance with the appropriate accounting standards and a true and fair view of the cash flows of the entity.

Summary of Inhalerx's Q4 2023 cash flow report

Inhalerx Limited (ASX: $IRX) has reported its quarterly cash flow for the quarter ended 31 December 2023. The report includes details of payments to related parties, confirming $56K paid as salary and fees to key management personnel, and $21K paid in directors fees. The compliance statement assures that the report has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A. Inhalerx expects to continue its operations and meet its business objectives, providing a positive outlook for the entity's future endeavors.